Show
Sort by
-
Pattern of infections observed during the maintenance phase in the PRIMA study
-
Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study
-
FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation
-
Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study
-
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma